• In the News

    June 12, 2016
    New NHANES Analysis Shows No Improvement in Last Decade to Get More Diabetes Patients to HbA1c Goal; Separate Study Suggests Reduced Efficacy in Real-World Plays Large Role Due to Adherence Falling Far Short of Clinical Trials

    Read more

  • Message from the CEO

    Intarcia Concludes FREEDOM Global Clinical Trial Program for ITCA 650 in Type 2 Diabetes with Four Consecutive Phase 3 Successes: Regulatory Filings Next

    FREEDOM-CVO, the last and the largest of the Phase 3 trials, showed ITCA 650 met its primary and secondary endpoints, satisfying CV safety requirements for regulatory filing.

    Read more

  • Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia

    What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"

    Hear Kurt Graves speak on this topic ›